161417-20-5Relevant articles and documents
3-pyridyloxymethyl heterocyclic ether compounds useful in controlling neurotransmitter release
-
, (2008/06/13)
Novel heterocyclic ether compounds of the formula: STR1 wherein n, *, R1, R2, R3 and y are specifically defined, or pharmaceutically acceptable salts or prodrugs thereof, which are useful in selectively controlling neurotransmitter release; therapeutically-effective pharmaceutical compositions of these compounds; and use of said compositions to selectively control neurotransmitter release in mammals.
Structure-activity studies on 2-methyl-3-(2(S)- pyrrolidinylmethoxy)pyridine (ABT-089): An orally bioavailable 3-pyridyl ether nicotinic acetylcholine receptor ligand with cognition-enhancing properties
Lin, Nan-Horng,Gunn, David E.,Ryther, Keith B.,Garvey, David S.,Donnelly-Roberts, Diana L.,Decker, Michael W.,Brioni, Jorge D.,Buckley, Michael J.,Rodrigues, A. David,Marsh, Kennan G.,Anderson, David J.,Buccafusco, Jerry J.,Prendergast, Mark A.,Sullivan, James P.,Williams, Michael,Arneric, Stephen P.,Holladay, Mark W.
, p. 385 - 390 (2007/10/03)
2-Methyl-3-(2(S)-pyrrolidinylmethoxy)pyridine, ABT-089 (S-4), a member of the 3-pyridyl ether class of nicotinic acetylcholine receptor (nAChR) ligands, shows positive effects in rodent and primate models of cognitive enhancement and a rodent model of anxiolytic activity and possesses a reduced propensity to activate peripheral ganglionic type receptors. The profiles of S-4, its N-methyl analogue, and the corresponding enantiomers across several measures of cholinergic channel function in vitro and in vivo are presented, together with in vitro metabolism and in vivo bioavailability data. On the basis of its biological activities and favorable oral bioavailability, S-4 is an attractive candidate for further evaluation as a treatment for cognitive disorders.